Dactylitis and Early Onset Psoriasis in Psoriatic Arthritis: Are they Markers of Disease Severity? A Clinical Study

Silvia Scriffignano · Fabio Massimo Perrotta · Mario di Marino · Francesco Ciccia · Ennio Lubrano

Received: April 30, 2022 / Accepted: May 24, 2022 / Published online: June 17, 2022 © The Author(s) 2022

ABSTRACT

Objectives: To stratify psoriatic arthritis (PsA) patients based on psoriasis (PsO) onset age: early onset psoriasis (EOP) vs. late onset psoriasis (LOP), and to assess if there are differences in disease characteristics, activity/function/impact of the disease, and comorbidity indices.

Methods: Cross-sectional analysis of a longitudinal PsA cohort. Patients were stratified based on PsO onset age.

Results: One hundred and sixty PsA patients were enrolled (84 in EOP and 76 in LOP group) in the study. EOP PsA patients seem to have an increased probability to have dactylitis rather than LOP ones, OR 9.64 (3.77–24.6). Comorbidity indices (Rheumatic Disease Comorbidity Index and Charlson Comorbidity Index) were higher in LOP PsA patients, but these data were not confirmed when adjusted by age and sex. There are also differences in the treatment regimen: EOP PsA patients were more frequently treated with anti-interleukin (IL) 17; instead, LOP patients were more frequently treated with non-steroid anti-inflammatory drugs and conventional synthetic disease-modifying anti-rheumatics drugs. There were no differences in the disease activity, function, or impact of the disease.

Conclusions: There are some clinical and therapeutic differences in PsA patients linked to the PsO onset age, namely dactylitis in EOP. Other characteristics found were: a “comorbidities trend” in LOP patients and a more frequent use of anti-IL17 in EOP.

Keywords: Psoriatic arthritis; Early onset psoriasis; Late onset psoriasis; Comorbidity indices; Dactylitis
Key Summary Points

**Why carry out this study?**

Among PsO patients, the PsO onset age distinguishes two different patterns: early onset psoriasis (0–40 years) and late-onset psoriasis (over 40 years). EOP has been identified as a more severe skin disease. Moreover, LOP in PsA patients has been associated with a higher cardiovascular risk.

The aim of the present study was to assess any differences in clinical characteristics, disease activity, impact of the disease, function, and comorbidities indices in a group of PsA patients when stratified by EOP and LOP.

**What was learned from the study?**

In our group of PsA patients, EOP is associated with a higher probability of dactylitis and a more frequent use of anti-IL17. In the LOP group, the assessed comorbidities indices tended to have a higher score, but these data were not confirmed when corrected by age and sex.

It could be useful to stratify PsA patients according to the PsO onset age for a clinical patients profiling. This, in turn, could help physicians in the disease severity assessment and in the clinical patients profiling. However, larger studies are needed to confirm these preliminary results.

INTRODUCTION

Psoriatic arthritis (PsA) and psoriasis (PsO) are chronic inflammatory diseases characterized by a wide phenotypic heterogeneity [1–3].

In 1985, Hensler and Christophers described two PsO phenotypes [4]:

- Early onset PsO (EOP) (or type 1 or “hereditary” form), a phenotype characterized by: onset at age 0–40 years, more extensive and severe skin involvement, association with human leukocyte antigen (HLA) Cw*06 and a PsO family history;
- Late-onset PsO (LOP) (or type 2), a phenotype characterized by: onset over 40 years, mild skin involvement, and the lack of both genetic association and PsO family history [4].

A recent analysis in PsO patients confirmed that HLA alleles explain a larger heritability of EOP, moving towards a genetic profiling to predict the PsO risk of a more severe phenotype [5]. The PsO stratification age among PsA patients was also assessed, showing that it could play a role in the clinical and genetic features of PsA patients [6, 7]. Furthermore, in PsA patients, LOP was described as an independent cardiovascular disease-associated factor [8].

Looking at this intriguing topic, the aim of the present study was to assess any differences in clinical characteristics, disease activity, impact of the disease, function, and comorbidities indices in a group of PsA patients when stratified by EOP and LOP.

METHODS

This is a cross-sectional analysis of a longitudinal PsA cohort, in which all PsA patients referred to the Rheumatology Unit of the University of Molise from January 1, 2019 to September 1, 2019 were considered eligible.

Inclusion criteria were:

- Age $\geq$ 18 years old,
- PsA, satisfying CIAssification criteria for Psoriatic ARthritis (CASPAR) [9],
- PsO confirmed by a dermatologist.

For each patient, age, sex, body mass index (BMI), smoking habits, PsO and PsA disease duration, predominant PsA subset at the time of the visit, PsO at the time of the visit (yes/no), body surface area (BSA) [10], uveitis, Crohn’s disease, ulcerative colitis, were collected.
To assess PsA disease activity, Patient Global Assessment, Physician’s global evaluation of disease activity [11], patient ‘pain on Visual Analogue Scale (VAS), tender/68 (TJC) and swollen/66 joint count (SwJC), Leeds Enthesitis Index [12], dactylitis (past, present, never) and C-reactive protein (CRP) were collected. Moreover, the following indices were calculated: Disease Activity for Psoriatic Arthritis and Minimal Disease Activity [13]. Finally, Health Assessment Questionnaire-Disability Index [14], Psoriatic Arthritis Impact of the Disease [15] and Patient Acceptable Symptoms State [16] were also performed.

For each patient, the current rheumatological therapy was collected. The Charlson Comorbidity Index (CCI), the Rheumatic Disease Comorbidity Index (RDCI) and the Functional Comorbidity Index (FCI) [17] (see Table S1 in the electronic supplementary material for details) were also calculated. Comorbidities were recorded based on previous diagnosis.

PsA patients were stratified in EOP (0–40 years) or LOP (over 40 years) and then compared to evaluate the potential differences in PsA disease characteristics, disease activity, impact of the disease, function, and comorbidity indices.

The study protocol followed the Declaration of Helsinki and was approved by the Institutional Review Board of the University of Molise (protocol n. 0002-09-2017).

**Statistical Analysis**

Statistical analysis was performed using the R software (version 3.6.2). All demographic and clinical characteristics were summarized by using descriptive statistics. Normally distributed variables were reported by mean ± standard deviation (SD), and non-normally distributed variables by median and inter-quartile range (IQR). The distribution of normality was evaluated by Kolmogorov–Smirnov test. Categorical data are shown as number (n.) and percentage (%) of valid data.

To compare EOP and LOP PsA patients, the \( \chi^2 \) test for independence and Student’s \( t \) test or Mann–Whitney \( U \) test were used.

Univariate logistic regression models were performed to analyze the association between EOP/LOP (independent factors), with all the clinical characteristics and comorbidity indices that showed a statistically significant difference between the two groups.

Multivariate logistic regression models were performed to adjust the significant association by sex and age when appropriate. Odds ratios (OR) were used as a measure of association and a statistical significance was defined as a two-tailed \( p \) value \( \leq 0.05 \).

**RESULTS**

Data of 160 PsA patients were considered for the study, 84 in the EOP group and 76 in the LOP one (Table 1). The proportion of females and males between the EOP and LOP PsA patients was similar, while the mean age (SD), as expected, was different: EOP PsA patients were younger, 51.9 (11.6), than LOP PsA ones, 62.3 (9.92), \( p < 0.001 \).

The only PsA clinical feature that statistically differed between EOP and LOP was dactylitis: \( n = 38 \) (45.2%) patients had dactylitis (present or past) among EOP patients vs. \( n = 6 \) patients (7.9%) among LOP patients, \( p < 0.001 \) (Table 1). These data were confirmed in the simple regression model (Table 2): EOP PsA patients have an increased probability of more than nine times to have dactylitis rather than LOP PsA patients, OR (CI95%) 9.64 (3.77–24.6), \( p < 0.001 \).

Another difference in the treatment was found: EOP PsA patients treated with anti-interleukin (IL) 17 drugs were statistically more numerous than LOP patients, respectively \( n = 22 \) (26.8%) and \( n = 10 \) (13.5%), \( p = 0.039 \). On the other hand, LOP PsA patients’ number on non-steroidal anti-inflammatory drugs (NSAIDs) and on conventional synthetic disease-modifying anti-rheumatics drugs (csDMARDs) was statistically higher, respectively \( n = 22 \) (29.7%) vs. \( n = 10 \) (12.2%), \( p = 0.016 \), and \( n = 16 \) (21.6%) vs. \( n = 6 \) (7.3%), \( p < 0.01 \).
Table 1  Demographic, clinical characteristics, therapy, and comorbidity indices of the PsA enrolled patients stratified in early onset PsO and late-onset PsO

| PsA patients | Overall, $n = 160$ | Early onset PsO $n = 84$ (52.5%) | Late-onset PsO $n = 76$ (47.5%) |
|--------------|--------------------|----------------------------------|---------------------------------|
| Demographic, physical characteristics, and smoking habits | | | |
| Sex, F, $n$ (%)—M, $n$, (%) | 30 (35.7)—54 (64.3) | 30 (39.5)—46 (60.5) |
| Age, mean (SD) | 51.9 (11.86)** | 62.3 (9.92)** |
| Weight (kg), median (IQR) | 72.5 (64–81) | 79 (72–82) |
| Height (cm), median (IQR) | 166 (163–175) | 169 (160–173) |
| BMI (kg/m²), median (IQR) | 25.2 (23.3–29.6) | 27.6 (24.3–30) |
| BMI $\geq 30$, $n$ (%) | 22/84 (26.2) | 22/76 (28.9) |
| Smoke, $n$ (%) | | | |
| Never smoke | 42/70 (60) | 34/60 (56.6) |
| Current smoke | 14/70 (20) | 14/60 (23.2) |
| Past smoke | 14/70 (20) | 14/60 (23.2) |
| Clinical PsA characteristics | | | |
| Disease duration (months), median (IQR) | 62 (24–120) | 74 (19.2–129.5) |
| PsA subset | | | |
| Axial, $n$ (%) | 12 (14.4) | 8 (10.5) |
| Monoarticular, $n$ (%) | 6 (7.1) | 4 (5.3) |
| Oligoarticular, $n$ (%) | 24 (28.6) | 24 (31.6) |
| Polyarticular, $n$ (%) | 32 (38.1) | 32 (42.1) |
| Enthesitic, $n$ (%) | 10 (11.9) | 8 (10.5) |
| Prevalent DIP involvement, $n$ (%) | 0 (0) | 0 (0) |
| Mutilans, $n$ (%) | 0 (0) | 0 (0) |
| Dactylitis, $n$ (%) | 38 (45.2)** | 6 (7.9)** |
| Uveitis present or past, $n$ (%) | 6 (7.1) | 0 (0) |
| Crohn’s disease, $n$ (%) | 2 (2.9) | 0 (0) |
| Ulcerative colitis, $n$ (%) | 0 (0) | 0 (0) |
| Psoriasis at the visit moment (yes), $n$ (%) | 56/82 (68.3) | 46/64 (71.8) |
| BSA, median (IQR) | 1 (0–2) | 1 (0–3) |
| Patient Global Assessment, median (IQR) | 4 (1–6) | 4 (2–6.25) |
| Patient pain on VAS, median (IQR) | 5 (2–7) | 5 (2.75–7) |
### Table 1 continued

| PsA patients | Overall, n = 160 | Early onset PsO n = 84 (52.5%) | Late-onset PsO n = 76 (47.5%) |
|--------------|-----------------|----------------|-----------------|
| **Tender joints/68, median (IQR)**  | 1 (0–4)     | 1.5 (0–5.25) |
| **Swollen joints/66, median (IQR)** | 0 (0–1)     | 0 (0–0.25) |
| **LEI, mean (± SD)**            | 0 (0–1)     | 0 (0–1) |
| **CRP (mg/dl), mean (± SD)**    | 0.2 (0.2–0.3) | 0.2 (0.2–0.6) |

**PsA activity, function and impact**

| DAPSA, median (IQR)       | 13 (5.1–17.6)  | 10.28 (5.0–17.4) |
|---------------------------|-----------------|------------------|
| MDA 5/7, n %              | 36/78 (46.1)    | 26/78 (38.2)     |
| MDA 7/7, n %              | 12/78 (15.38)   | 8/78 (11.8)      |
| PsAID, median (IQR)       | 2.70 (1–5.27)   | 2.32 (1.1–4.14)  |
| PASS yes, n (%)           | 48/76 (63.15)   | 36/54 (66.6)     |
| HAQ-DI, median (IQR)      | 0.5 (0.125–0.687) | 0.5 (0.125–0.812) |

**Therapy**

| NSAIDs, n (%)      | 10/82 (12.2)* | 22/74 (29.7)* |
|-------------------|---------------|---------------|
| Oral corticosteroids, n (%) | 4/82 (4.9) | 2/74 (2.7) |
| csDMARDs, n (%)    | 6/82 (7.3)*   | 16/74 (21.6)* |
| Methotrexate, n (%)| 6/82 (7.3)*   | 14/74 (18.9)* |
| Sulfasalazine, n (%)| 0/82 (0) | 2/74 (2) |
| Anti-TNF-α, n (%)  | 28/82 (34.1)  | 30/74 (40.5)  |
| Anti-IL-17, n (%)   | 22/82 (26.8)* | 10/74 (13.5)* |
| Anti-IL12-23, n (%) | 6/82 (7.3) | 4/74 (5.4) |
| iPDE4, n (%)        | 8/82 (9.7)    | 6/74 (8.1)    |

**Comorbidities indices**

| CCI ≥ 1 | 14/84 (16.6)* | 26/76 (34.2)* |
| FCI ≥ 1 | 36/84 (42.8)  | 44/76 (57.9)  |
With regard to comorbidities, the patients with CCI ≥ 1 and a RDCI ≥ 1 were numerous in LOP group: CCI ≥ 1: n = 26 (34.2%) vs. n = 14 (16.6%), p = 0.01, respectively, in LOP and EOP; RDCI ≥ 1: n = 54 (71%) vs. n = 36 (42.8%), respectively, in LOP and EOP, p < 0.001 (Table 1).

In the univariate model, LOP showed a positive association with CCI ≥ 1 and RDCI ≥ 1: LOP PsA patients, rather than EOP ones, have an increased probability of 2.6 times to have a CCI ≥ 1 and of 3.27 times to have a RDCI ≥ 1 (Table 3). However, when these data were corrected by age and sex, the association was not confirmed (Table 3).

**DISCUSSION**

In this study, we compared EOP and LOP PsA patients; in the first group, dactylitis seems to be more prevalent. Moreover, focusing on comorbidities indices, CCI and RDCI scores tend to be higher in LOP PsA patients, but these results could be related to the patients’ age.

The PsO onset age is considered as a severity marker in PsO patients. In fact, EOP is associated with extensive skin disease, strong family aggregation, and HLA-Cw*06 positivity, when compared to the LOP [18]. However, for PsA, a definition of severity is still lacking; in 2005, Brockbanck et al. proposed dactylitis as a clinical marker of disease severity because of its association with a greater degree of radiological damage [19]. This concept is in keeping with a recent study in which early PsA patients (DMARDs-naïve) with dactylitis seem to have a greater burden of disease (greater SwJC, TJC, CRP, ultrasound synovitis and erosive damage) [20] when compared to early PsA patients without dactylitis. Therefore, it could be supposed that EOP is also a marker of severity in PsO, due to the association that we found between EOP and dactylitis. The early onset of PsO could be a potential clinical marker of PsA severity. If other future larger studies will confirm this association, EOP and dactylitis could be considered as potential additional factors to take into account for a tight control in a treat-to-target strategy [21, 22].

Moreover, while the assessment of PsA disease activity is standardized and well defined, the way to collect comorbidities is still an open question.
unmet need [17]. In our study, we assessed comorbidities through three different comorbidity indices (CCI, RDCI, and FCI), finding an association between LOP with CCI ≥ 1 and RDCI ≥ 1, but these results were not confirmed when adjusted for patients’ age and sex. These data probably suggest that in our group of patients, there is a “comorbidity trend” in LOP patients, but other factors (like age) could have an influence.

Another intriguing point to consider is that EOP PsA patients were more frequently on anti-IL17 therapy, underlying that EOP PsA patients often require a more robust “skin-driven” treatment. In fact, these patients, having a longstanding history of skin disease, had more previous systematic treatments, including tumor necrosis factor-α inhibitors (data not shown) when compared to LOP. This difference could also be linked to a different management between EOP and LOP patients because it is more likely that EOP patients had a first evaluation carried out in a dermatological setting, as previously shown [23].

The main limitation of our study is due to the monocentric and cross-sectional design of the analysis.

### Table 3 Univariate logistic regression analysis to assess the association between LOP and RDCI ≥ 1 and CCI ≥ 1; multivariate logistic regression analysis in which these results were adjusted for sex and age

|            | Univariate OR (CI 95%) | p value | Multivariate OR (CI 95%) | p value |
|------------|------------------------|---------|--------------------------|---------|
|            |                        |         |                          |         |
| RDCI ≥ 1   |                        |         |                          |         |
| LOP (vs. EOP) | 3.27 (1.70–6.32)      | < 0.001 | 1.83 (0.88–3.81)         | 0.104   |
| Sex (F)    | –                      | –       | 1.37 (0.67–2.81)         | 0.387   |
| Age (years)| –                      | –       | 1.07 (1.03–1.10)         | < 0.001 |
| CCI ≥ 1    |                        |         |                          |         |
| LOP (vs. EOP) | 2.60 (1.23–5.47)      | 0.012   | 2.10 (0.92–4.76)         | 0.075   |
| Sex (F)    | –                      | –       | 0.61 (0.27–1.36)         | 0.231   |
| Age (years)| –                      | –       | 1.02 (0.99–1.06)         | 0.167   |

EOP early onset psoriasis, LOP late-onset psoriasis, RDCI Rheumatic Disease Comorbidity Index, OR (CI 95%) odd ratio (confidence interval 95%)

### CONCLUSIONS

This study confirmed that there are some clinical differences in PsA patients linked to the PsO onset age, namely dactylitis in EOP, “comorbidities trend” in LOP patients and a more frequent use of anti-IL17 in EOP.

### ACKNOWLEDGEMENTS

**Funding.** No funding or sponsorship was received for this study or publication of this article. All authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis.

**Authorship.** All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

**Authorship Contributions.** All authors have made substantial contributions to all of these sections: conception and design of the study,
acquisition of data, analysis and interpretation of data, drafting the article, revising it critically for important intellectual content, and final approval of the version to be submitted.

**Disclosures.** Silvia Scriffignano, Fabio Massimo Perrotta, Mario di Marino, Francesco Ciccia and Ennio Lubrano have nothing to disclose.

**Compliance with Ethics Guidelines.** All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study. The study was approved by the Institutional Review Board of the University of Molise.

**Data Availability.** The datasets generated during and/or analyzed during the current study are not publicly available but are available from the corresponding author on reasonable request.

**Open Access.** This article is licensed under a Creative Commons Attribution-Non-Commercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, and indicate if changes were made.

**REFERENCES**

1. FitzGerald O, Ogdie A, Chandran V, et al. Psoriatic arthritis. Nat Rev Dis Primers. 2021;7(1):59.
2. Griffiths CEM, Armstrong AW, Guðjónsson JE, Barker JNWN. Psoriasis. Lancet. 2021;397:1301–15.
3. Lubrano E, Scriffignano S, Perrotta FM. Psoriatic arthritis, psoriatic disease, or psoriatic syndrome? J Rheumatol. 2019;46:1428–30.
4. Henseler T, Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol. 1985;13:450–6.
5. Zhou Y, Cai M, Sheng Y, Xuejun Z. A large-scale, stratified genetic analysis of the major histocompatibility complex region in early- and late-onset psoriasis in China. Ann Dermatol. 2021;33:61–7.
6. Queiro R, Alperi M, Alonso-Castro S, et al. Patients with psoriatic arthritis may show differences in their clinical and genetic profiles depending on their age at psoriasis onset. Clin Exp Rheumatol. 2012;30:476–80.
7. Bilgin E, Aydin SZ, Tinazzi I, et al. Disease characteristics of psoriatic arthritis patients may differ according to age at psoriasis onset: cross-sectional data from the Psoriatic Arthritis-International Database. Clin Exp Rheumatol. 2021;39:532–6.
8. Queiro R, Lorenzo A, Tejón P, Pardo E, Coto P, Ballina J. Polyarticular evolution and late-onset psoriasis may be associated with cardiovascular disease in psoriatic arthritis. Int J Rheum Dis. 2019;22:269–74.
9. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54:2665–73.
10. Ashcroft DM, Wan Po AL, Williams HC, Griffiths CE. Clinical measures of disease severity and outcome in psoriasis: A critical appraisal of their quality. Br J Dermatol. 1999;141:185–91.
11. Lubrano E, Perrotta FM, Parsons WJ, Marchesoni A. Patient’s global assessment as an outcome measure for psoriatic arthritis in clinical practice: a surrogate for measuring low disease activity? J Rheumatol. 2015;42:2332–8.
12. Healy PJ, Helliwell PS. Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis. Arthritis Rheum. 2008;59: 686–91.
13. Lubrano E, De Socio A, Perrotta FM. Comparison of composite indices tailored for psoriatic arthritis treated with csDMARD and bDMARD: a cross-sectional analysis of a longitudinal cohort. J Rheumatol. 2017;44:1159–64.

14. Ranza R, Marchesoni A, Calori G, et al. The Italian version of the Functional Disability Index of the Health Assessment Questionnaire. A reliable instrument for multicenter studies on rheumatoid arthritis. Clin Exp Rheumatol. 1993;11:123–8.

15. Gossec L, de Wit M, Kiltz U, et al. A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. Ann Rheum Dis. 2014;73:1012–9.

16. Lubrano E, Scriffignano S, Azuaga AB, Ramirez J, Canete JD, Perrotta FM. Assessment of the Patient Acceptable Symptom State (PASS) in psoriatic arthritis: association with disease activity and quality of life indices. RMD Open. 2020;6: e001170.

17. Lubrano E, Scriffignano S, Perrotta FM. Multimorbidity and comorbidity in psoriatic arthritis—a perspective. Expert Rev Clin Immunol. 2020;16: 963–72.

18. Ferrándiz C, Pujol RM, García-Patos V, Bordas X, Smandia JA. Psoriasis of early and late onset: a clinical and epidemiologic study from Spain. J Am Acad Dermatol. 2002;46:867–73.

19. Brockbank JE, Stein M, Schentag CT, Gradman DD. Dactylitis in psoriatic arthritis: a marker for disease severity? Ann Rheum Dis. 2005;64:188–90.

20. Dubash S, Alabas OA, Michelena X, et al. Dactylitis is an indicator of a more severe phenotype independently associated with greater SJC, CRP, ultrasound synovitis and erosive damage in DMARD-naïve early psoriatic arthritis. Ann Rheum Dis. 2022;81:490–5.

21. Smolen JS, Braun J, Dougados M, et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis. 2014;73:6–16.

22. Lubrano E, Scriffignano S, De Socio A, Perrotta FM. Analysis of potential determinants for a treat-to-target strategy in psoriatic arthritis patients from a real-world setting. Clin Exp Rheumatol. 2019;37: 512.

23. Lubrano E, Delle Sedie A, Romanelli M, et al. Management of psoriatic arthritis in rheumatology and dermatology settings: sub-analysis of the Italian population from the international LOOP study. Clin Rheumatol. 2021;40:2251–62.